Anson Funds Management’s AIM ImmunoTech AIM Stock Holding History

Anson Funds Management’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-5,156	Closed	-$393	–	101
2019 Q3	$393	Buy	+5,156	New	+$1.25M	0.29%	26
2017 Q3	–	Sell	-210	Closed	-$462K	–	72
2017 Q2	$462K	Buy	+210	New	+$519K	0.15%	36
2017 Q1	–	Sell	-244	Closed	-$739K	–	103
2016 Q4	$739K	Sell	244 -55	-18%	-$222K	0.23%	40
2016 Q3	$1.65M	Buy	+299	New	+$2.1M	0.36%	36

Other funds holding AIM

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Anson Funds Management's AIM Position: Q4 2019 in Review

Anson Funds Management sold out of AIM ImmunoTech (AIM) in Q4 2019, closing a stake of 5,156 shares — an estimated $393 sold.

Anson Funds Management first reported a position in AIM in Q3 2016 and held it in 4 quarters. The position peaked at $1.65M in Q3 2016. 9 funds tracked by Wall St. Rank hold AIM as of Q4 2019.

Anson Funds Management reported no remaining AIM ImmunoTech position as of Q4 2019 after selling out during the quarter.
Anson Funds Management sold 5,156 AIM ImmunoTech shares in Q4 2019, an estimated $393.
Anson Funds Management first reported a position in AIM ImmunoTech in Q3 2016 and held it in 4 quarters.
Anson Funds Management's AIM ImmunoTech position peaked at $1.65M in Q3 2016.
9 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q4 2019.

Based on Anson Funds Management's 13F filing for Q4 2019, filed 14 Feb 2020.